• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

PhoreMost Ltd.

PhoreMost has developed a next-generation phenotypic drug discovery technology called SITESEEKER®, which uses the power of live-cells to discern the best new targets for future therapy and crucially, how to drug them. Based on ‘Protein Interference’ (PROTEINi®); a new genome-wide target identification & validation platform created by PhoreMost, SITESEEKER® can now systematically reveal critical druggable target-sites in any particular disease setting and then convert this information rapidly into novel small-molecule therapeutics. Using SITESEEKER®, PhoreMost is exclusively developing first-in-class targets for a range of unmet diseases and will collaborate with other pharmaceutical companies also wishing to engage in ‘Drugging the Undruggable®’. www.phoremost.com *

 

	Start	2015-04-07 established
	Industry	drug discovery
	Industry 2	Siteseeker® drug target discovery technology
	Person	Torrance, Chris (PhoreMost 201504– CEO + Co-founder before Horizon Discovery Co-founder + Vernalis)
	Person 2	Milner, Jonathan (Abcam 201409 Deputy Chairman + largest shareholder before CEO + Co-founder)
	Region	Babraham, Cambridgeshire
	Country	United Kingdom (GB)
	Street	Building B580, Room 2011 Babraham Research Campus
	City	CB22 3AT Babraham, Cambridgeshire
	Tel	+44-1223-804163
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for �About Section�: PhoreMost Ltd.. (3/10/16). "Press Release: PhoreMost and The Wistar Institute Collaborate to Identify New Druggable Targets in Cancer, Immunotherapy and Aging". Cambridge.
		Record changed: 2020-11-10

Advertisement

More documents for PhoreMost Ltd.

• [1] PhoreMost Ltd.. (11/9/20). "Press Release: PhoreMost and Oxford Biomedica Enter Gene Therapy Discovery Collaboration". Cambridge & Oxford....
• [2] PhoreMost Ltd.. (9/8/20). "Press Release: PhoreMost and XtalPi Sign AI-based Pharmaceutical drug Discovery Collaboration Agreement". Cambridge & Cambridge, MA....
• [3] PhoreMost Ltd.. (1/7/20). "Press Release: PhoreMost and Boehringer Ingelheim Enter Multi-project Drug Discovery Collaboration". Cambridge....
• [4] PhoreMost Ltd.. (7/8/19). "Press Release: PhoreMost and inStem Enter Structural Biology Alliance". Cambridge....
• [5] Ligand Pharmaceuticals Inc.. (6/12/19). "Press Release: Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology". San Diego, CA & Cambridge....
• [6] PhoreMost Ltd.. (6/21/18). "Press Release: PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery Programs". Cambridge....
• [7] PhoreMost Ltd.. (5/15/18). "Press Release: PhoreMost Completes $15M (£11M) Series A Round to Enter Drug Discovery". Cambridge....
• [8] NeoPhore Ltd.. (4/11/18). "Press Release: NeoPhore Appoints Jeffrey Roix as Chief Executive Officer"....
• [9] PhoreMost Ltd.. (10/12/16). "Press Release: PhoreMost Ltd and University of Cambridge Collaborate to Identify Innovative Drug Targets for Neurodegenerative Disease". Cambridge....
• [10] PhoreMost Ltd.. (3/10/16). "Press Release: PhoreMost and The Wistar Institute Collaborate to Identify New Druggable Targets in Cancer, Immunotherapy and Aging". Cambridge....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2021. Made in Germany.